Curious how AI is making a big splash in the world of synthetic biology? Absci Founder and CEO Sean McClain recently chatted with SynBioBeta’s Jenna Gallegos about the shift from the big data problem to the small data problem, why synbio could be the key to unlocking the high-quality, high-throughput data needed to train machine learning models, and how AI can potentially enable better therapeutic target selection. Read more here: https://lnkd.in/gMax8PWV #AI #Biologics #DrugDiscovery
Absci
Biotechnology Research
Vancouver, Washington 11,803 followers
Creating Drugs at the Speed of Ai
About us
Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.
- Website
-
http://www.absci.com
External link for Absci
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Vancouver, Washington
- Type
- Public Company
- Founded
- 2011
- Specialties
- generative AI, synthetic biology, biologics, drug discovery, antibody development, artificial intelligence, pharmaceuticals, and biotechnology
Locations
-
Primary
Vancouver, Washington 98683, US
Employees at Absci
Updates
-
Absci is gearing up for a busy 2025 with lead AI-designed candidate ABS-101 anticipated to enter the clinic. Discover how Absci's growing AI-designed pipeline programs are advancing through preclinical development. As Genetic Engineering & Biotechnology News’ Alex Philippidis has the full story: https://lnkd.in/gS_eb7fS
-
Imagine a career where you can make a real-world impact. At #Absci, that's our everyday reality as we’re bringing together cutting-edge technologies in AI and synthetic biology in pursuit of our mission to create better biologics for patients, faster. We have openings across various roles. Apply now to become an Unlimiter: https://lnkd.in/ejayi8E #AI #Biologics #DrugDiscovery
Careers | Absci
https://www.absci.com
-
Thank you to everyone who joined us in Boston this week at our symposium “Unlocking High-Throughput Biology in Drug Discovery” co-hosted with Carterra. A special thanks to our guest speaker Philip Kim, Professor at the University of Toronto, for presenting a great talk on AI and therapeutic discovery. Also thank you to our presenters and thought leaders from Merck, GSK, and Carterra. Absci’s David Eavarone, PhD, Director, High-Throughput Screening, and Amir S., Staff AI Scientist, shared our AI approach in their presentation, “Generative AI powered by high-throughput screening for antibody design". #Absci #AI #Biologics #DrugDiscovery
-
Absci is excited to welcome Shelby Walker as Chief Legal Officer! Shelby has been at the forefront of cutting-edge biotechnologies and we’re excited for her to join us as we establish a new paradigm in AI drug creation. Help us give Shelby a warm welcome with a like or a comment below!👇
-
Absci partners with some of the top biopharma, tech, and academic institutions in the industry to advance AI-driven antibody design to create better biologics for patients, faster. Nature's Biopharma Dealmakers shares more insight on why major biopharma companies like AstraZeneca and Almirall are partnering with Absci to pioneer the application of artificial intelligence tools to develop therapeutic antibodies: https://lnkd.in/gVkeXCX8 #Absci #AI #Biologics #DrugDiscovery
Antibody design enters the AI era
nature.com
-
Join us and thought leaders from Merck, GSK, the University of Toronto, and Carterra next Tuesday in Boston at our symposium “Unlocking High-Throughput Biology in Drug Discovery” co-hosted with Carterra. Absci’s David Eavarone, PhD, Director, High-Throughput Screening, and Amir S., Senior AI Scientist, will present a talk on “Generative AI powered by high-throughput screening for antibody design". Learn more: https://lnkd.in/gqtAk2mf #Absci #AI #Biologics #DrugDiscovery
-
Absci reposted this
At Absci, we are looking for a seasoned HR Director with a strong background in the biotech industry. We value our team of Unlimiters, who are integral to our mission to revolutionize drug discovery, and for looking for someone passionate about Employee Relations and Learning & Development. If you know someone who could be a great fit or if someone within your network comes to mind, I would truly appreciate your referral. I want to thank you in advance for any introductions or shares of this post.
-
We were excited to have Prof Sir Mene Pangalos, Absci Board Member and co-chair of our Scientific Advisory Board, at Absci HQ this week to meet with the team and discuss our AI platform and AI-designed pipeline programs. A highlight of the visit was a fireside chat with Sean McClain where we learned more about Mene’s experience building leading R&D teams and pipelines at AstraZeneca, and heard his insights on how Absci can continue to advance our platform and pipeline to bring better biologics to patients, faster. #Absci #AI #Biologics #DrugDiscovery
-
Join us at the Goldman Sachs 45th Annual Healthcare Conference next Monday and learn how we’re combining AI with scalable wet lab technologies to create better biologics for patients, faster. Stream online here: https://lnkd.in/g7RcHU5W #Absci #AI #Biologics #DrugDiscovery